Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul 24;398(10297):299-300.
doi: 10.1016/S0140-6736(21)01427-6.

Tocilizumab in COVID-19 therapy: who benefits, and how?

Avidan U Neumann  1 , Mehmet Goekkaya  2 , Karim Dorgham  3 , Claudia Traidl-Hoffmann  4 , Guy Gorochov  5
Affiliations
Comment

Tocilizumab in COVID-19 therapy: who benefits, and how?

Avidan U Neumann et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment in

Comment on

References

    1. RECOVERY Collaborative Group Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645. - PMC - PubMed
    1. Lescure FX, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9:522–532. - PMC - PubMed
    1. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636–1643. - PMC - PubMed
    1. Dorgham K, Quentric P, Goekkaya M, et al. Distinct cytokine profiles associated with COVID-19 severity and mortality. J Allergy Clin Immunol. 2021;147:2098–2107. - PMC - PubMed
    1. Galvan-Roman JM, Rodriguez-Garcia SC, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol. 2020;147:72–80. - PMC - PubMed

Substances